S3 peptide TFA
Based on 1 Customer Validation
S3 peptide is a multifunctional synthetic peptide that acts as a LIMK1 inhibitor with an IC50 of 40 μg/mL. S3 peptide blocks cofilin phosphorylation and SDF-1α (HY-P4911)-induced T cell chemotaxis, and reduces viral particle production of HIV-1 and M-PMV. S3 peptide forms dimers via intermolecular disulfide bonds to bind and disrupt LPS micelles, exerting anti-Gram-negative bacterial activity. S3 peptide serves as a targeting moiety for NKA α1 and is used for the construction of PET tracers. S3 peptide is applicable to research related to HIV-1 infection, M-PMV infection, breast cancer, liver cancer and non-small cell lung cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.19%
- Formule: C174H282N52O41S2·xC2HF3O2
- Masse moléculaire:3822.55 (free base)
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Activité biologique
Description
|
human LIMK1 40 μg/mL (IC50) |
HIV-1 |
In Vitro
S3 peptide (30 μM; 24 h) potently inhibits LIMK1-mediated phosphorylation of cofilin in HeLa and Cos-1 cells[1].
The S3 peptide (10-40 μg/mL) potently inhibits the in vitro kinase activity of LIMK1 isolated from SDF-1α (HY-P4911)-stimulated Jurkat human leukemia T cells in a dose-dependent manner[2].
S3 peptide (40 μg/mL; 30 min) inhibits SDF-1α-induced phosphorylation of cofilin and actin rearrangement in Jurkat human leukemia T cells, while induces chemotactic responses and reduces cell migration levels to near basal levels[2].
The S3 peptide (0.2 μM) binds to negatively charged PC/PG large unilamellar vesicles via a simple adhesion process, with a partition coefficient of 3.8×104, and does not form large aggregates[3].
The S3 peptide (0.2 μM) localizes to the surface of negatively charged PC/PG large unilamellar vesicles, where it interacts specifically with the wild-type S4 peptide (but not with S4 mutants), alters its localization state, and partially protects it from cleavage by proteinase K[3].
The S3 peptide (0.2 μM) specifically co-assembles with the wild-type S4 peptide on negatively charged PC/PG giant unilamellar vesicles, but does not co-assemble with the S4 mutant[3].
The S3 peptide (29.1 μM) specifically interacts with the wild-type S4 peptide in negatively charged PC/PG giant unilamellar vesicles, but does not bind to the S4 mutant, resulting in a moderate increase in the helicity of the peptide complex[3].
S3 peptide (with peptide/lipid molar ratios up to 0.24) does not permeabilize negatively charged PC/PG large unilamellar vesicles, but in this membrane environment, it dose-dependently inhibits the membrane permeabilizing activity of wild-type S4 peptide (but not S4 mutants)[3].
The S3 peptide (0.125-4.00 μM; 3 h) exhibits higher binding affinity for immobilized E. coli O111:B4 LPS than its monomeric form, and reaches binding saturation at 2 μM in ELISA-based LPS binding assays[4].
The S3 peptide (5-20 μg/μL; 30 min pre-incubation, 3-4 h phage incubation) mediates the specific binding of S3 phages to MDA-MB-231 breast cancer cells; a dose-dependent inhibitory effect on phage binding is observed[5].
S3 peptide (80 μM; 4 h) colocalizes with NKA α1 in MDA-MB-231 breast cancer cells[5].
The S3 peptide targets NKA α1 as its primary target, since knockout of NKA α1 in MDA-MB-231 breast cancer cells reduces the binding rate of S3 phage by 2.7 to 4.4-fold[5].
The S3 peptide is associated with S3 phage binding activity, which is positively correlated with the expression of NKA α1 in 9 breast cancer cell lines, with a Pearson correlation coefficient of 0.9705[5].
S3 peptide (30 μM; 48 h) significantly reduces the release of HIV-1 particles in HeLa cells[1].
S3 peptide (30 μM; 48 h) significantly reduces the release of M-PMV particles in Cos-1 cells[1].
S3 peptide (30 μM; 2 h) induces statistically significant clustering of HIV-1 Gag punctate structures on the plasma membrane of HeLa cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Jurkat human leukemic T cells
-
Concentration:40 μg/mL
-
Incubation Time:30 min (preincubation prior to 1 min SDF-1α stimulation)
-
Result:Completely inhibited the SDF-1α-induced increase in β-actin (filamentous actin) staining observed in control cells at 1 min post-stimulation.
Completely inhibited the SDF-1α-induced increase in P-cofilin staining observed in control cells at 1 min post-stimulation.
-
Cell Line:Jurkat human leukemic T cells
-
Concentration:40 μg/mL
-
Incubation Time:30 min (preincubation prior to 3 h chemotaxis assay)
-
Result:Reduced SDF-1α-induced chemotaxis to near basal levels.
Reduced chemotaxis to ~150% of control, compared to ~300% of control with SDF-1α alone.
-
Cell Line:E. coli
-
Concentration:0.125, 0.25, 0.5, 1, 2 and 4 μM
-
Incubation Time:3 h
-
Result:Exhibited significantly higher binding affinity for immobilized E. coli O111:B4 LPS than its monomeric counterpart (S3-C27S mutant) over a concentration range of 0.125-4.00 μM following a 3-hour incubation at room temperature.
Reached binding saturation at 2 μM, whereas the monomeric S3-C27S peptide continued to bind in a linear fashion without reaching saturation under the same conditions.
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:5 μg/μL, 10 μg/μL, 20 μg/μL (pre-incubated for 30 min)
-
Incubation Time:3-4 h (phage incubation)
-
Result:Reduced S3 phage binding to ~70% at 5 μg/μL.
Reduced S3 phage binding to ~55% at 10 μg/μL.
Reduced S3 phage binding to ~40% at 20 μg/μL.
Exhibited highest binding affinity to MDA-MB-231 cells among six tested high-repeat phage clones, with an OD450nm value ~2.5.
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:80 μM
-
Incubation Time:4 h
-
Result:Co-localized with NKA α1 protein in MDA-MB-231 cells, as visualized by overlapping green (streptavidin-FITC) and red (AF594) fluorescence signals in merged confocal images.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice were subcutaneously injected with 1 × 107 MDA-MB-231 cells mixed with 20% Matrigel to establish a breast cancer xenograft model, and the mice were subjected to imaging experiments when tumor volumes reached approximately 300 mm3[5]
-
Dosage:1×1010 PFU (S3 phage); 0.5 mg/kg (Cy5-S3); 3.7 MBq (18F-AlF-NOTA-S3); 200 μg (unlabelled S3 peptide for blocking)
-
Administration:i.v.; single dose (S3 phage allowed to circulate for 2 h; unlabelled S3 peptide administered 30 min before radiotracer)
-
Result:Accumulated at significantly higher levels in tumor tissue (21.5×106 pfu/g) compared to lung (4.3×106 pfu/g), heart (3.5×106 pfu/g), and brain (5.4×106 pfu/g).
Showed high tumor-specific accumulation at 24 hours post-injection, with radiant efficiency in tumors (8×109) dramatically higher than in normal organs (heart, liver, spleen, lung, kidney, brain all <1×109).
Reached peak tumor uptake at 60 minutes post-injection, with tumor uptake measured at 5.1378 %ID/g.
Tumor-to-skin, tumor-to-heart, tumor-to-liver, and tumor-to-bone ratios at 60 minutes were 7.74226, 4.8665, 4.3864, and 2.073, respectively.
Reduced tumor uptake to 2.0133 %ID/g when pre-injected as unlabelled peptide for blocking studies.
Chemical Information
-
Appearance Solid
-
Masse moléculaire 3822.55 (free base)
-
Formule C174H282N52O41S2·xC2HF3O2
-
Color White to off-white
-
SMILES
O=C(N[C@@H](C)C(N[C@@H](CO)C(NCC(N[C@@H](C(C)C)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(NCC(N[C@@H](C(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC2=CNC3=CC=CC=C23)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCSC)C(N[C@@H](CCCCN)C(N[C@@H](CC5=CNC6=CC=CC=C56)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCSC)N.O=C(O)C(F)(F)F.[x]
-
Sequence
Met-Ala-Ser-Gly-Val-Ala-Val-Ser-Asp-Gly-Val-Ile-Lys-Val-Phe-Asn-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys
-
Sequence Shortening
MASGVAVSDGVIKVFNRQIKIWFQNRRMKWKK
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Protocole
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Research Protocol for Cancer Immunology
Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Chemotaxis Gradient Chamber Assay 1
The chemotaxis gradient chamber assay is based on the principle of observing directional cell migration in response to a stable, linear or quasi-linear concentration gradient of a chemoattractant formed between two fluid reservoirs separated by a narrow observation chamber. Cells placed within the chamber respond to the gradient by polarized movement toward higher chemoattractant concentrations, allowing quantification of chemotactic behavior in real time under microscopy. The classic Zigmond chamber design enables simultaneous visualization of gradient formation and individual cell trajectories, making it suitable for studying leukocyte chemotaxis and other motile cell types in vitro.
-
Under-Agarose Cell Migration Assay
The under-agarose cell migration assay is a classical in vitro chemotaxis method designed to evaluate directed cell movement through a semi-solid agarose matrix toward soluble chemoattractant gradients, enabling visualization and quantification of leukocyte or motile cell migration in a confined 2D-like environment. In this system, cells and chemoattractants are placed in separate wells cut into an agarose gel, allowing diffusion-driven gradient formation that guides directional migration, which is typically assessed by measuring migration distance, cell morphology changes, and accumulation toward the chemoattractant source. This assay has been widely used to study neutrophil and leukocyte chemotaxis as a simple alternative to filter-based migration systems and allows direct microscopic observation of migrating cells under near-physiological confinement conditions.
-
Transwell/Boyden Chamber Migration Assay
The Transwell/Boyden chamber migration assay measures cell movement through a porous membrane separating an upper and lower chamber, usually after a chemoattractant gradient is established by placing cells in the upper chamber and chemoattractant-containing medium in the lower chamber. The readout is generated by quantifying cells that traverse the membrane and appear on the lower membrane surface or in the lower chamber, depending on whether the cell type is adherent or non-adherent. This assay reflects chemotactic or haptotactic migration rather than matrix invasion unless an extracellular-matrix barrier is added to the membrane.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Chemotaxis Gradient Chamber Assay 2
Chemotaxis gradient chamber assays measure directional cell migration in response to a soluble chemical gradient by imaging cells as they move across a defined observation region; the readout is generated from time-lapse cell trajectories, displacement toward the gradient, forward migration index, trajectory plots, rose/polar plots, and statistical tests of non-random directionality. The Dunn chamber is a direct-viewing glass chamber in which cells migrate across a bridge between control and chemoattractant wells, allowing observation of cells in a linear concentration gradient; related direct-viewing formats include the Insall chamber, which supports defined unidirectional gradients and high numerical-aperture microscopy, and the μ-Slide Chemotaxis chamber, which supports long-term live-cell imaging and gradient characterization with fluorescent dye.
Pureté et documentation
-
Fiche technique (295 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Wen X, et al. ROCK1 and LIM kinase modulate retrovirus particle release and cell-cell transmission events. Journal of virology. 2014 Jun;88(12):6906-21. [Content Brief]
[2]. Nishita M, et al. Stromal cell-derived factor 1alpha activates LIM kinase 1 and induces cofilin phosphorylation for T-cell chemotaxis. Molecular and cellular biology. 2002 Feb;22(3):774-83. [Content Brief]
[3]. Verma R, et al. Phospholipid membrane-interaction of a peptide from S4 segment of KvAP K(+) channel and the influence of the positive charges and an identified heptad repeat in its interaction with a S3 peptide. Biochimie. 2011 Jun;93(6):1001-11. [Content Brief]
[4]. Li P, et al. Perturbation of Lipopolysaccharide (LPS) Micelles by Sushi 3 (S3) antimicrobial peptide. The importance of an intermolecular disulfide bond in S3 dimer for binding, disruption, and neutralization of LPS. J Biol Chem. 2004 Nov 26;279(48):50150-6. [Content Brief]
[5]. Wang Q, et al. Identification of a sodium pump Na/K ATPase α1-targeted peptide for PET imaging of breast cancer. Journal of controlled release : official journal of the Controlled Release Society. 2018 Jul 10;281:178-188. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)